Archives of Plastic Surgery

Korean Society of Plastic and Reconstructive Surgeons (대한성형외과학회)
권호 표지

Effect of Oncostatin M on Wound Healing Activity of Diabetic Fibroblasts in vitro

Oncostatin M이 당뇨 환자 섬유모세포의 창상치유능에 미치는 영향

  • Lim, Hyung Woo (Department of Plastic Surgery, Korea University College of Medicine) ;
  • Chun, Kyung Wook (Department of Plastic Surgery, Korea University College of Medicine) ;
  • Han, Seung-Kyu (Department of Plastic Surgery, Korea University College of Medicine) ;
  • Kim, Woo Kyung (Department of Plastic Surgery, Korea University College of Medicine)
  • 임형우 (고려대학교 의과대학 성형외과학교실) ;
  • 전경욱 (고려대학교 의과대학 성형외과학교실) ;
  • 한승규 (고려대학교 의과대학 성형외과학교실) ;
  • 김우경 (고려대학교 의과대학 성형외과학교실)
  • Received : 2008.03.11
  • Published : 2008.07.10
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Oncostatin M(OSM) has been known as a role in fibrosis and anti-inflammatory effects of various organs and tissues. Although there have been a number of studies which are focused on the roles and mechanisms of OSM, there are few reports on its effects in chronic wound healing. The purpose of this study is to evaluate the effects of OSM in wound healing activities of dermal fibroblasts of chronic wound in vitro. In particular, this study is focused on cell proliferation and synthesis of collagen and glycosaminoglycan(GAG), which are the major components of the extracellular matrices, of diabetic fibroblasts. Methods: Fibroblasts were isolated from excess skin that was obtained from diabetic foot ulcer patients who underwent debridement. The isolated fibroblasts were cultivated in presence of OSM(100 ng/mL). Cell proliferation, collagen synthesis and GAG levels were compared. Results: All the components tested in this study increased in OSM treatment group. In particular, collagen and GAG synthesis demonstrated statistically significant increases(p<0.05 in the Mann-Whitney U-test). Conclusion: These results indicate that OSM increases wound healing activities of dermal fibroblasts of chronic wound in vitro.

Keywords

References

  1. Han SK, Choi KJ, Kim WK: Clinical application of fresh fibroblast allografts for the treatment of diabetic foot ulcers: a pilot study. Plast Reconstr Surg 114: 1783, 2003 https://doi.org/10.1097/01.PRS.0000142415.57470.DF
  2. Cavallini M: Autologous fibroblasts to treat deep and complicated leg ulcers in diabetic patients. Wound Repair Regen 15: 35, 2007 https://doi.org/10.1111/j.1524-475X.2006.00182.x
  3. Hibi M, Nakajima K, Hirano T: IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med 74: 1, 1996 https://doi.org/10.1007/BF00202068
  4. Brown TJ, Lioubin MN, Marquardt H: Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol 139: 2977, 1987
  5. Scaffidi AK, Mutsaers SE, Moodley YP, McAnulty RJ, Laurent GJ, Thompson PJ, Knight DA: Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol 136: 793, 2002 https://doi.org/10.1038/sj.bjp.0704769
  6. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D: Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 271: 32635, 1996 https://doi.org/10.1074/jbc.271.51.32635
  7. Richards CD, Shoyab M, Brown TJ, Gauldie J: Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 150: 5596, 1993
  8. Wallace PM, Macmaster JF, Rillema JR, Rouleau KA, Hanson MB, Burstein SA, Shoyab M: In vivo properties of oncostatin M. Ann N Y Acad Sci 762: 42, 1995
  9. Wallace PM, Macmaster JF, Rouleau KA, Brown TJ, Loy JK, Donaldson KL, Wahl AF: Regulation of inflammatory responses by oncostatin M. J Immunol 162: 5547, 1999
  10. Chun KW, Han SK, Lee BI, Kim WK: Optimal concentration of OSM for wound healing activity of fibroblasts. J Korea Wound Care Soc 2: 77, 2006
  11. Goren I, Kampfer H, Muller E, Schiefelbein D, Pfeilschifter J, Frank S: Oncostatin M expression is functionally connected to neutrophils in the early inflammatory phase of skin repair: Implications for normal and diabetes-impaired wounds. J Invest Dermatol 126: 628, 2006 https://doi.org/10.1038/sj.jid.5700136
  12. Broughton G 2nd, Janis JE, Attinger CE: Wound healing: an overview. Plast Reconstr Surg 117(7 Suppl): 1e-S, 2006 https://doi.org/10.1097/01.prs.0000194899.01875.d6
  13. Hehenberger K, Kratz G, Hansson A, Brismar K: Fibroblasts derived from human chronic diabetic wounds have a decreased proliferation rate, which is recovered by the addition of heparin. J Dermatol Sci 16: 144, 1998 https://doi.org/10.1016/S0923-1811(97)00042-X
  14. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1, 2003 https://doi.org/10.1042/BJ20030407
  15. Ihn H, Tamaki K: Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway. J Immunol 165: 2149, 2000 https://doi.org/10.4049/jimmunol.165.4.2149